ORIGINAL ARTICLEHip osteoarthritis: short-term efficacy and safety of viscosupplementation by hylan G-F 20. An open-label study in 22 patients
Section snippets
Patients and methods
Inclusion criteria for this prospective open-label study were as follows: age 18 years or older, presence of American College of Rheumatology criteria for hip osteoarthritis 〚2〛, Kellgren radiological grade no greater than 3 〚3〛, confirmation of the diagnosis by computed tomography in patients with Kellgren grade I disease, a visual analog scale (VAS) score for pain ≥ 40 mm and/or a Lequesne index ≥ 6 〚4〛, persistence of the pain for longer than 1 month despite use of analgesics or nonsteroidal
Results
From December 1999 to July 2000, 22 patients were included in the study and received one or two hylan GF 20 injections (table I). Eight patients received two injections, yielding 30 injections in all.
On day 7, six patients had a 50% reduction in the Lequesne index (i.e., a response) and seven had a 50% reduction in the VAS pain score.
On day 30, 11 patients had a response (50% or greater reduction in the Lequesne index). Ten patients had a 50% or greater reduction in their VAS pain score (table
Discussion
The open-label design, absence of a control group, and small sample size limit the relevance of our results. In contrast, our definition of a response as an at least 50% improvement in the Lequesne index versus baseline limits the risk of bias related to an injection-induced placebo effect. Six patients met our criterion for a response on day 7; this early improvement may have been related either to the lubricating effect of hyaluronate in ‘dry’ joints, as reported in studies of
Conclusion
The limited number of patients treated with viscosupplementation for hip osteoarthritis and the absence of controlled studies make it premature to recommend this treatment modality. However, our results are encouraging given that most patients received a single injection. The results would probably be better with two or three injections. The best candidates may be patients who are too young for total hip arthroplasty and those who are older but have contraindications to this procedure. Further
References (15)
- et al.
A pilot clinical evaluation of the treatment of hip osteoarthritis with hyaluronic acid
Curr Therap Res
(1994) - et al.
Que penser des injections intra-articulaires dans le traitement de la gonarthrose?
- et al.
The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip
Arthritis Rheum
(1991) - et al.
Radiologic assessment of osteoarthrosis
Ann Rheum Dis
(1957) - et al.
Indexes of severity for osteoarthritis of the hip and knee. Validation. Value in comparison with other assessment tests
Scand J Rheumatol
(1987) - et al.
Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints
Pathol Biol (Paris)
(1974) Management of osteoarthritis of the knee joint
Cited by (73)
Hip Inflammation MRI Scoring System (HIMRISS) to predict response to hyaluronic acid injection in hip osteoarthritis
2018, Revue du Rhumatisme (Edition Francaise)Is Intra-Articular Hyaluronic Acid Effective in Treating Osteoarthritis of the Hip Joint?
2015, Journal of ArthroplastyCitation Excerpt :Twenty-three of 286 manuscripts met the overall inclusion criteria for this study (Fig. 1). Overall there were six prospective randomized controlled trials [3–8] (Level 2), fifteen prospective studies [9–23] and two retrospective studies [24,25] (Table 1). We assessed each study to determine if they were either retrospective or prospective and we assessed the overall power of each study to determine quality.
Effectiveness and tolerance of Hylan GF 20 during omarthrosis without cuff rupture. An open, prospective and multicentric study
2009, Revue du Rhumatisme (Edition Francaise)Viscosupplementation for hip osteoarthritis: Does systematic review of patient-reported outcome measures support use?
2020, Journal of OrthopaedicsCitation Excerpt :Therefore, our final analysis included 39 studies which reported on a total of 5,864 patients receiving injections of HA (Table 1). A total of 16 studies utilized the Lequesne Index (LI) to report outcomes following viscosupplementation.19–34 Of these, 15 analyses reported decreases in LI scores following the administration of HA, with 13 studies reporting significant reductions at their respective time frames21–33 (Table 2).